It is very uncertain whether INTERMITTENT (GRADUALLY INCREASED DRUG‐FREE PERIODS) changes leaving the study early/ loss to compared with MAINTENANCE THERAPY (very low certainty).
It is very uncertain whether INTERMITTENT (DRUG HOLIDAY) changes leaving the study early/ loss to compared with MAINTENANCE THERAPY (very low certainty).
It is very uncertain whether ANY INTERMITTENT DRUG TECHNIQUE changes leaving the study early/ loss to compared with PLACEBO (very low certainty).
RISPERIDONE showed no clear difference in leaving the study early: any reason compared with PERHENAZINE ‒ long‐term data (low certainty).
RISPERIDONE showed no clear difference in leaving the study early: any reason compared with ZIPRASIDONE ‒ long‐term data (> 12 months) (low certainty).
It is very uncertain whether zuclopenthixol dihydrochloride (Cis Z isomer) changes leaving the study early: Any reason compared with zuclopenthixol (Cis Z/Trans E isomer) (very low certainty).
YOGA probably leads to lower leaving the study early: short term compared with NON‐STANDARD CARE (moderate certainty).
Adjunctive antioxidants for schizophrenia showed no clear difference in leaving the study early, short term compared with placebo (moderate certainty).
It is very uncertain whether RISPERIDONE changes leaving the study early ‒ any reason compared with CLOZAPINE ‐ all data short term (very low certainty).
Zuclopenthixol dihydrochloride may leads to lower leaving the study early (any reason) compared with chlorpromazine (low certainty).
It is very uncertain whether zuclopenthixol dihydrochloride changes leaving the study early (any reason) compared with chlorprothixene (very low certainty).
It is very uncertain whether zuclopenthixol dihydrochloride changes leaving the study early (any reason) compared with haloperidol (very low certainty).
It is very uncertain whether zuclopenthixol dihydrochloride changes leaving the study early (any reason) compared with sulpiride (very low certainty).
It is very uncertain whether zuclopenthixol dihydrochloride changes leaving the study early (any reason) compared with thiothixene (very low certainty).
It is very uncertain whether zuclopenthixol dihydrochloride changes leaving the study early (any reason) compared with zuclopenthixol depot (very low certainty).
CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) probably leads to lower leaving the study early ‐ any reason compared with HIGH DOSE (> 800 mg/day ‐ all medium term) (moderate certainty).
CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) showed no clear difference in leaving the study early ‐ any reason compared with MEDIUM DOSE (401 mg/day to 800 mg/day) (moderate certainty).
It is very uncertain whether ASENAPINE changes leaving the study early ‐ any reason compared with PLACEBO (very low certainty).